Retatrutide 5mg Dosage & Mixing Guide

What is Retatrutide?

Retatrutide (LY3437943) is a novel triple-receptor agonist that targets GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors simultaneously. It represents the newest generation of incretin-based peptides for metabolic research.

The triple mechanism provides complementary effects: GIP and GLP-1 receptor activation for glucose metabolism and appetite control, plus glucagon receptor activation for enhanced energy expenditure and lipid metabolism. This three-pronged approach has shown remarkable results in early clinical trials.

The 5mg vial is suitable for initial titration phases of research protocols.

Quick Reference

Reconstitution Guide

Materials Needed

• Retatrutide 5mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare your workspace — Clean your work area and gather all materials. Wash hands thoroughly.

2. Clean the vial stoppers — Wipe the Retatrutide vial stopper and BAC water vial with alcohol swabs. Allow to dry.

3. Draw the BAC water — Using a sterile syringe, draw 1mL of bacteriostatic water.

4. Add water to peptide vial — Insert the needle and slowly inject BAC water down the inside wall of the vial. Never spray directly onto the powder.

5. Allow to dissolve — Retatrutide typically dissolves within 5-10 minutes. Gently swirl if needed — never shake.

6. Verify dissolution — Solution should be clear and colorless. Discard if cloudy or particles visible.

7. Label and store — Write reconstitution date on vial. Refrigerate immediately.

Alternative Reconstitution Options

Dosage Protocol

Concentration Calculations

With 5mg peptide in 1mL BAC water:

• Concentration: 5mg/mL = 5000mcg/mL
• Per unit (U-100 syringe): 50mcg per unit

Common Dose Calculations

Doses Per Vial

At 5mg/mL concentration (1mL total = 5mg):

Suggested Titration Protocol

Retatrutide research protocols employ gradual escalation similar to other incretins:

Important Notes:

• Minimum 4 weeks at each dose level before escalation
• The 5mg vial is most practical for weeks 1-8 (doses 1-2mg)
• Transition to 10mg vials for doses above 4mg for cost efficiency
• Titration schedule may be adjusted based on research objectives

Injection Guide

Subcutaneous Administration

1. Clean injection site with alcohol swab and let dry
2. Pinch skin fold at abdomen, thigh, or upper arm
3. Insert needle at 90° angle
4. Inject slowly over 5-10 seconds
5. Wait 10 seconds before withdrawing
6. Apply gentle pressure — do not massage

Site Rotation

Rotate weekly between:

• Abdomen (preferred) — avoid 2-inch radius around navel
• Front/outer thigh
• Back of upper arm

Consistency tip: Administer on the same day each week to maintain steady levels.

Storage Requirements

Lyophilized (Powder Form)

• Temperature: -20°C (-4°F) or colder
• Duration: 2+ years
• Conditions: Protect from light and moisture

Reconstituted (Mixed with BAC Water)

• Temperature: 2-8°C (36-46°F)
• Duration: 4-6 weeks
• Conditions: Protect from light, never freeze

Research Considerations

Triple Mechanism of Action

Retatrutide’s unique three-receptor approach:

GIP Receptor Activation:

• Enhanced insulin secretion
• Improved beta-cell function
• Adipose tissue effects

GLP-1 Receptor Activation:

• Appetite suppression
• Delayed gastric emptying
• Glucagon suppression

Glucagon Receptor Activation:

• Increased energy expenditure
• Enhanced lipid oxidation
• Hepatic effects on glucose output

Key Research Findings

Phase 2 clinical trial results demonstrated:

• Mean weight reduction up to 24% at highest doses
• Superior efficacy compared to dual-agonists
• Improvements in metabolic parameters
• Novel insights into multi-receptor pharmacology

Comparison to Other Incretins

When to Use 5mg Vials

The 5mg vial is recommended for:

• Initial titration — Weeks 1-8 at 1-2mg doses
• Pilot studies — Testing tolerance before larger commitment
• Cost-conscious start — Assessing response before purchasing larger vials

For maintenance at higher doses (8-12mg), the 10mg vial is more economical.

Sourcing for Research

Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Scientific References

1. Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Randomized Controlled Trial.” N Engl J Med. 2023;389:514-526.
2. Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes: A Randomised, Double-blind, Placebo and Active-controlled, Parallel-group, Phase 2 Trial.” Lancet. 2023;402:529-544.
3. Coskun T, et al. “LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss.” J Clin Endocrinol Metab. 2022;107(11):3144-3155.

Last updated: December 03, 2025

Disclaimer: This information is for educational and research purposes only. Retatrutide is a research peptide not intended for human consumption. It is currently in clinical development and not approved for any medical use. Always follow applicable laws and institutional guidelines.